Preliminary safety and efficacy of GX-17, a long-acting interleukin-7, in combination with pembrolizumab in patients with refractory or recurrent metastatic triple negative breast cancer (mTNBC): Dose escalation period of Phase Ib/II study (KEYNOTE-899).
Preliminary safety and efficacy of GX-17, a long-acting interleukin-7, in combination with pembrolizumab in patients with refractory or recurrent metastatic triple negative breast cancer (mTNBC): Dose escalation period of Phase Ib/II study (KEYNOTE-899).
저자
Sohn, Joohyuk; Park, Kyong Hwa; Ahn, Hee Kyung; Lee, Keun Seok; Kim, Jee Hyun; Kim, Sung-Bae; Lee, Kyoung Eun; Kim, Jee Hung; Yang, Se Hwan; Le, Ngocdiep T.; Kim, Jiwon; Heo, MinKyu; Woo, Jung-Won; Sung, Young Chul; Im, Young Hyuck